Treatment approaches for elderly/unfit patients with AML ineligible for intensive chemotherapy

Treatment strategies for patients with IDH1/2-mutated AML ineligible for intensive chemotherapyПодробнее

Treatment approaches for patients with TP53m AML ineligible for high intensity chemotherapyПодробнее

Patients With ND AML Unfit for Intensive Chemotherapy: Tailoring TreatmentПодробнее

Dr. Patel on Delaying Treatment for Elderly Patients With Newly Diagnosed AMLПодробнее

Managing AML in elderly patientsПодробнее

Treatment options for patients with AML that are not candidates for intensive chemotherapyПодробнее

Oral combination of HMAs + venetoclax in unfit or elderly patients with AMLПодробнее

Novel approaches to treating AML in elderly patientsПодробнее

Conversations in AML: Novel Therapies Targeting the Immune System for Elderly/Unfit PatientsПодробнее

Tapan M. Kadia - Non-Intensive Treatment of Older Unfit Patients with AMLПодробнее

Standard treatment of elderly patients with AML & evaluating IDH inhibitors in younger patientsПодробнее

Assessing Untreated AML Patients Who Are Ineligible for Intensive ChemotherapyПодробнее

Can Venetoclax plus Azacitidine Help AML Patients Ineligible for Intensive Treatment?Подробнее

A new era for elderly AML patientsПодробнее

Conversations in AML: Novel Therapies Targeting the Immune System for Elderly/Unfit PatientsПодробнее

What is the optimum treatment strategy for elderly or frail patients with AML?Подробнее

The complications of treating elderly patients with AMLПодробнее

Prolonging survival in patients with AML ineligible for intensive chemotherapyПодробнее

Breakthroughs in the treatment of elderly patients with AMLПодробнее